Subscribe
agreement-istock-480052842_mediaphotos
mediaphotos / iStockphoto.com
19 April 2018Americas

TM oppositions against Pfizer suspended amid negotiations

Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Medtech company backs down from Pfizer TM oppositions
14 August 2018   Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Medtech company backs down from Pfizer TM oppositions
14 August 2018   Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations.

More on this story

Americas
Medtech company backs down from Pfizer TM oppositions
14 August 2018   Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations.

More features

Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m